Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2021-09-21 00:00:00 ET · period of report 2021-09-17 · accession 0001562180-21-006038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-21 | 2021-09-17+ | SNDX | Morrison Briggs | CEO, Dir | S - Sale+OE | $20.07 | -70.3K | 48.3K | -59% | -$1.41M |
| DM | 2021-09-21 | 2021-09-17+ | SNDX | Morrison Briggs | CEO, Dir | M - OptEx | $7.20 | +70.3K | 118.6K | +146% | +$506.2K |
| DM | 2021-09-21 | 2021-09-17+ | SNDX | Morrison Briggs | CEO, Dir | M - OptEx | $0.00 | -70.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-20 | S | D | 50 | $20.00 | 48,336 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-20 | M | A | 50 | $7.20 | 48,386 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-17 | S | D | 70,262 | $20.07 | 48,336 | D | — | — | (F2) The sale prices ranged from $20.00 to $20.32. |
| 4 | Common | Common Stock | 2021-09-17 | M | A | 70,262 | $7.20 | 118,598 | D | — | — | |
| 5 | Derivative | Stock Options (Right to buy) | 2021-09-17 | M | D | 70,262 | $0.00 | 0 | D | $7.20 · — to 2025-06-30 | 70,262 Common Stock | (F3) This option is fully vested. |
| 6 | Derivative | Stock Options (Right to buy) | 2021-09-20 | M | D | 50 | $0.00 | 0 | D | $7.20 · — to 2025-06-30 | 50 Common Stock | (F3) This option is fully vested. |